Citigroup’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Citigroup’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-663	Closed	-$743	–	6086
2025 Q2	$743	Buy	+663	New	+$741	﹤0.01%	5421
2025 Q1	–	Sell	-1,971	Closed	-$4.47K	–	5592
2024 Q4	$4.47K	Buy	+1,971	New	+$3.64K	﹤0.01%	5475
2021 Q3	–	Sell	-183	Closed	-$10K	–	5762
2021 Q2	$10K	Sell	183 -135	-42%	-$7.21K	﹤0.01%	5645
2021 Q1	$18K	Sell	318 -293	-48%	-$22.1K	﹤0.01%	5301
2020 Q4	$41K	Buy	611 +336	+122%	+$45.8K	﹤0.01%	6180
2020 Q3	$70K	Sell	275 -149	-35%	-$30.5K	﹤0.01%	5359
2020 Q2	$71K	Buy	424 +119	+39%	+$12.8K	﹤0.01%	5813
2020 Q1	$21K	Buy	305 +122	+67%	+$9.52K	﹤0.01%	6648
2019 Q4	$12K	Sell	183 -14	-7%	-$812	﹤0.01%	7131
2019 Q3	$12K	Buy	197 +184	+1,415%	+$10.9K	﹤0.01%	6978
2019 Q2	$1K	Hold	13	–	–	﹤0.01%	7658
2019 Q1	$1K	Hold	13	–	–	﹤0.01%	7566
2018 Q4	$1K	Hold	13	–	–	﹤0.01%	7554
2018 Q3	$1K	Sell	13 -12	-48%	-$725	﹤0.01%	7645
2018 Q2	$1K	Hold	25	–	–	﹤0.01%	7512
2018 Q1	$1K	Hold	25	–	–	﹤0.01%	7424
2017 Q4	$1K	Hold	25	–	–	﹤0.01%	7459
2017 Q3	$2K	Hold	25	–	–	﹤0.01%	7011
2017 Q2	$2K	Hold	25	–	–	﹤0.01%	6963
2017 Q1	$2K	Hold	25	–	–	﹤0.01%	6983
2016 Q4	$1K	Hold	25	–	–	﹤0.01%	7102
2016 Q3	$1K	Hold	25	–	–	﹤0.01%	6971
2016 Q2	$1K	Hold	25	–	–	﹤0.01%	6968
2016 Q1	$1K	Sell	25 -10	-29%	-$367	﹤0.01%	7275
2015 Q4	$1K	Buy	+35	New	+$1.44K	﹤0.01%	7357
2015 Q3	–	Sell	-2	Closed	–	–	7374
2015 Q2	$0	Sell	2 -62	-97%	-$3.7K	﹤0.01%	7511
2015 Q1	$4K	Buy	+64	New	+$4.05K	﹤0.01%	6756

Other funds holding BCLI

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BSB

Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.53B AUM 17.43% 1-Year Est. Return

Citigroup's BCLI Position: Q3 2025 in Review

Citigroup sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 663 shares — an estimated $743 sold.

Citigroup first reported a position in BCLI in Q1 2015 and held it in 27 quarters. The position peaked at $71K in Q2 2020. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

Citigroup reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
Citigroup sold 663 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $743.
Citigroup first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2015 and held it in 27 quarters.
Citigroup's BRAINSTORM CELL THERAPUTC position peaked at $71K in Q2 2020.
5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.